Mannkind (MNKD), the biopharmaceutical Company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer, continues to perform well. The Company's lead product candidate, AFREZZA inhalation powder, an ultra-rapid-acting insulin therapy is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Although the Company has yet to receive FDA approval, the stock hasn't disappointed SCN Members. We suggested MNKD to our readers on June 22nd at $2.06 per share before the stock ran to a high of $2.92. The move represented a MNKD, however, it appears shares of MNKD are again gaining steam.

Still up over 25% on the idea after the stock pulled back a bit in recent weeks, shares of MNKD once again look very attractive on the weekly chart I've included here. The stock has found upward momentum in recent weeks, which is evident by sellers' failed attempt back in late July early August to keep the stock below its 3X3 DMA (blue line) shown here. The pullback appears to have been just that, a breather before making another move to try and break above the $2.92 ceiling, which it has failed to break twice before. Will three times be the charm? If shares of MNKD can break above that $2.92 level, this is going to be one fun stock to own. Any positive news out of the Company or from the FDA could mean MNKD's share price was as low as it was ever going to go back in early August.

Strictly from a technical perspective, now that the stock is trading back above the 3X3 on the weekly chart, this small biotech again has the wind at its back.

http://www.smallcapnetwork.com/SCN-Featured-Stock-Updates-CALL-MNKD-and-CRAY/s/article/view/p/mid/7/id/1158/

Yahoo!

Google

Digg

Facebook

Del.ico.us

Friendster

Twitter

LinkedIn

StumbleUpon

Reddit

Newsvine

FriendFeed

Netvibes

Tumblr

Mister Wong

WebNews

Squidoo

Diigo

Blinklist

Folkd